Reference
Kawaguchi I, et al. A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan. Advances in Therapy : 5 Dec 2019. Available from: URL: https://doi.org/10.1007/s12325-019-01166-3
Rights and permissions
About this article
Cite this article
Glecaprevir/pibrentasvir dominates current DAAs for hep C in Japan. PharmacoEcon Outcomes News 844, 16 (2020). https://doi.org/10.1007/s40274-020-6479-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6479-0